Reported Earlier, Arrowhead Reports Plozasiran Also Reduced Pancreatitis Risk In Severe Triglyceride Patients
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a Hot Line
Arrowhead's new medicine plozasiran helped patients with very high triglycerides (a type of fat in blood) and also lowered the risk of pancreatitis, which is a painful problem. This is good news for the company because it shows their medicine works better than they might have hoped.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.